1. Search Result
Search Result
Results for "

p27

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

5

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

9

Antibodies

1

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114712
    SJ572403
    3 Publications Verification

    SJ403

    CDK Others
    SJ572403 (SJ403) is a p27 Kip1 inhibitor. SJ572403 has high specificity for specific regions within the D2 subdomain of p27-KID with a Kd value of 2.2 mM. SJ572403 can be used for the research of diseases associated with intrinsically disordered proteins (IDPs) .
    SJ572403
  • HY-123578
    NSC689857
    1 Publications Verification

    EGFR E1/E2/E3 Enzyme Cancer
    NSC689857 is a potent EGFR and SCF SKP2 inhibitor with an IC50 value of 36 μM for Skp2-Cks1. NSC689857 can inhibit p27 ubiquitylation (IC50=30 μM). NSC689857 has varied activity across cancer types, with more activity against leukemia cell lines than others .
    NSC689857
  • HY-16230

    ROS Kinase Apoptosis Cancer
    GGTI-2417 is a potent and selective inhibitor of GGTase I. GGTI-2417 inhibits the Cdk2-mediated phosphorylation of p27 Kip1 at Thr187 and accumulates p27 Kip1 in the nucleus. GGTI-2417 also induces breast cancer cell apoptosis .
    GGTI-2417
  • HY-15694
    SMIP004
    4 Publications Verification

    E1/E2/E3 Enzyme Apoptosis Cancer
    SMIP004 is a SKP2 E3 ligase inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective apoptosis inducer of human prostate cancer cells .
    SMIP004
  • HY-15301

    E1/E2/E3 Enzyme Cancer
    CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC50=1.72 μM) inhibits the ubiquitination of p27 Kip1, as confirmed by dose-response analysis.
    CC0651
  • HY-P11013

    CDK Cancer
    p27, a CDK inhibitor, is a SCFSkp2/Cks1 substrate. p27 can be used for the study of cancer .
    p27
  • HY-P11020

    E1/E2/E3 Enzyme Cancer
    p27 Analogue CP2 is a macrocyclic peptide inhibitor targeting the SCFSkp2/Cks1 E3 ubiquitin ligase (Kd=32 nM). p27 Analogue CP2 blocks SCFSkp2/Cks1-mediated ubiquitylation and degradation of p27, restoring p27 levels and inhibiting cell proliferation. p27 Analogue CP2 is promising for research of cancers dependent on Skp2 overexpression such as breast cancer .
    p27 Analogue CP2
  • HY-117513

    Proteasome Apoptosis Cancer
    CEP1612 is a dipeptidyl proteasome inhibitor with the IC50 of 60 nM. CEP1612 induces p21(WAF1)and p27(KIP1) expression and cell apoptosis. CEP1612 shows anticancer activity in vivo .
    CEP1612
  • HY-N13904

    Proteasome Cancer
    Argyrin A, a cyclical peptide, is a potent antitumoral agent. Argyrin A exerts its effects through a potent inhibition of the proteasome. Argyrin A leads to increased endogenous p27 kip1 levels by preventing protein turnover .
    Argyrin A
  • HY-P1404

    Pim Cancer
    R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase .
    R8-T198wt
  • HY-16231

    Apoptosis Cancer
    GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors .
    GGTI-2418
  • HY-126075A

    E1/E2/E3 Enzyme Cancer
    WS-383 is a potent, selective and reversible inhibitor of DCN1-UBC12 interaction, with an IC50 of 11 nM. WS-383 inhibits Cul3/1 neddylation, induces accumulation of p21, p27 and NRF2 .
    WS-383
  • HY-100237
    SZL P1-41
    Maximum Cited Publications
    12 Publications Verification

    E1/E2/E3 Enzyme Apoptosis Cancer
    SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities .
    SZL P1-41
  • HY-135199

    E1/E2/E3 Enzyme Cancer
    Ubiquitination-IN-1 (compound 24) is a ubiquitination and Cksl-Skp2 protein-protein interaction (IC50=0.17 μM) inhibitor. Ubiquitination-IN-1 increases levels of p27. Ubiquitination-IN-1 has the potential for treatment disease by blocking the degradation of tumor suppressors .
    Ubiquitination-IN-1
  • HY-114310

    VD/VDR Apoptosis Cancer
    VDR agonist 1 (compound 28) is a nonsteroidal Vitamin D receptor (VDR) agonist, with an IC50 of 690 nM in MCF-7 cells. VDR agonist 1 arrests the cell cycle through the up-regulation of p21 and p27, promotes apoptosis by increasing the expression of BAX and decrease the expression of Bcl-2 .
    VDR agonist 1
  • HY-126075

    E1/E2/E3 Enzyme Cancer
    WS-383 free base is a potent, selective and reversible inhibitor of DCN1-UBC12 interaction, with an IC50 of 11 nM. WS-383 free base inhibits Cul3/1 neddylation, induces accumulation of p21, p27 and NRF2 .
    WS-383 free base
  • HY-112158
    NSC139021
    1 Publications Verification

    ERGi-USU

    Ser/Thr Kinase Cancer
    NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling .
    NSC139021
  • HY-N13944

    Apoptosis Cancer
    Argyrin F a cyclic peptide with antitumoral activities. Argyrin F inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis and epithelial-mesenchymal transition (EMT). Argyrin F stabilizes p27 kip, up-regulated p21 waf1/cip1 and depletes COX2. Argyrin F can be used for the study of pancreatic ductal adenocarcinoma (PDAC) .
    Argyrin F
  • HY-106263B

    PTEN PDK-1 MDM-2/p53 Apoptosis Akt Cancer
    Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .
    Tyroserleutide hydrochloride
  • HY-115893A

    CDK Cancer
    P18IN005 hydrochloride is a novel inhibitor of p18, exhibiting potent activity in negatively regulating haematopoietic stem cell (HSC) self-renewal. P18IN005 hydrochloride has been shown to be more effective than p27 in inhibiting HSC self-renewal in mouse models. P18IN005 hydrochloride promotes the expansion of functional HSCs in short-term cultures. P18IN005 hydrochloride serves as a valuable tool for dissecting the signaling pathways involved in stem cell self-renewal.
    P18IN005 hydrochloride
  • HY-W412264

    Pim Cancer
    Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer .
    Pim-1/2 kinase inhibitor 1
  • HY-12286

    Proteasome Apoptosis Autophagy Caspase Bcl-2 Family NF-κB PARP Cancer
    PI-1840 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α .
    PI-1840
  • HY-115932

    Aurora Kinase Apoptosis Cancer
    Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents .
    Aurora kinase-IN-1
  • HY-19486

    Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related Inflammation/Immunology
    UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27 KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .
    UR-1505
  • HY-N0704
    Agrimol B
    1 Publications Verification

    Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial Infection Metabolic Disease Cancer
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .
    Agrimol B
  • HY-121605

    Apoptosis Cancer
    RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .
    RL71
  • HY-121605S

    Isotope-Labeled Compounds Apoptosis Cancer
    RL71-d6 is a deuterium labeled RL71 (HY-121605). RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .
    RL71-d6
  • HY-173007

    Akt PI3K Anaplastic lymphoma kinase (ALK) CDK Apoptosis Mitochondrial Metabolism Cancer
    ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids .
    ALK/PI3K/AKT-IN-1
  • HY-RS11330

    Small Interfering RNA (siRNA) Others

    PSMD9 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMD9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PSMD9 Human Pre-designed siRNA Set A
    PSMD9 Human Pre-designed siRNA Set A
  • HY-RS21546

    Small Interfering RNA (siRNA) Others

    Dctn6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dctn6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dctn6 Mouse Pre-designed siRNA Set A
    Dctn6 Mouse Pre-designed siRNA Set A
  • HY-149216

    Others Cancer
    Anticancer agent 103 (Compound 2k) is a potent anticancer agent .
    Anticancer agent 103
  • HY-RS16419

    Small Interfering RNA (siRNA) Others

    DCTN6 Human Pre-designed siRNA Set A contains three designed siRNAs for DCTN6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DCTN6 Human Pre-designed siRNA Set A
    DCTN6 Human Pre-designed siRNA Set A
  • HY-RS19053

    Small Interfering RNA (siRNA) Others

    Cdkn1b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdkn1b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdkn1b Mouse Pre-designed siRNA Set A
    Cdkn1b Mouse Pre-designed siRNA Set A
  • HY-RS06553

    Small Interfering RNA (siRNA) Others

    IFI27 Human Pre-designed siRNA Set A contains three designed siRNAs for IFI27 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IFI27 Human Pre-designed siRNA Set A
    IFI27 Human Pre-designed siRNA Set A
  • HY-N3825

    Apoptosis Cancer
    ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells .
    ent-Kaurane-3α,16β,17-triol
  • HY-RS14639

    Small Interfering RNA (siRNA) Others

    TMED7 Human Pre-designed siRNA Set A contains three designed siRNAs for TMED7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TMED7 Human Pre-designed siRNA Set A
    TMED7 Human Pre-designed siRNA Set A
  • HY-RS25543

    Small Interfering RNA (siRNA) Others

    Cdkn1b Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdkn1b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdkn1b Rat Pre-designed siRNA Set A
    Cdkn1b Rat Pre-designed siRNA Set A
  • HY-10446R

    Reference Standards Antifolate Apoptosis Cancer
    Pralatrexate (Standard) is the analytical standard of Pralatrexate. This product is intended for research and analytical applications. Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pralatrexate (Standard)
  • HY-10446
    Pralatrexate
    5+ Cited Publications

    Antifolate Apoptosis Cancer
    Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Pralatrexate
  • HY-N8884

    PTEN Akt NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Coelonin is a dihydrophenanthrene with anti-inflammation activity. Coelonin inhibits LPS-induced PTEN phosphorylation. Coelonin inhibits NF-κB activation and p27Kip1 degradation by regulating the PI3K/AKT pathway negatively. Coelonin can inhibit IκBα phosphorylation and degradation and increases the expression of IκBα protein .
    Coelonin
  • HY-D0014
    Brilliant blue G-250
    3 Publications Verification

    Biochemical Assay Reagents Others
    Brilliant Blue G-250 is a dye commonly used for the visualization of proteins separated by SDS-PAGE, offering a simple staining procedure and high quantitation. In the Bradford protein assay, protein concentrations are determined by the absorbance at 595 nm due to the binding of Brilliant Blue G-250 to proteins. Brilliant Blue G-250 is a safe highly selective P2×7R antagonist with promising consequent inactivation of NLRP3 inflammasome .
    Brilliant blue G-250

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: